KR20180012833A - 피지의 과잉 생산과 연관된 피부 상태를 치료하기 위한 폴리펩티드 및 항체 - Google Patents

피지의 과잉 생산과 연관된 피부 상태를 치료하기 위한 폴리펩티드 및 항체 Download PDF

Info

Publication number
KR20180012833A
KR20180012833A KR1020177037904A KR20177037904A KR20180012833A KR 20180012833 A KR20180012833 A KR 20180012833A KR 1020177037904 A KR1020177037904 A KR 1020177037904A KR 20177037904 A KR20177037904 A KR 20177037904A KR 20180012833 A KR20180012833 A KR 20180012833A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
polypeptide
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177037904A
Other languages
English (en)
Korean (ko)
Inventor
창이즈 태그히비글로우
유 티엔 왕
Original Assignee
창이즈 태그히비글로우
유 티엔 왕
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 창이즈 태그히비글로우, 유 티엔 왕 filed Critical 창이즈 태그히비글로우
Publication of KR20180012833A publication Critical patent/KR20180012833A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177037904A 2015-05-29 2016-05-27 피지의 과잉 생산과 연관된 피부 상태를 치료하기 위한 폴리펩티드 및 항체 Ceased KR20180012833A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168374P 2015-05-29 2015-05-29
US62/168,374 2015-05-29
PCT/CA2016/050605 WO2016191864A1 (en) 2015-05-29 2016-05-27 Polypeptides and antibodies to treat skin conditions associated with overproduction of sebum

Publications (1)

Publication Number Publication Date
KR20180012833A true KR20180012833A (ko) 2018-02-06

Family

ID=57439738

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177037904A Ceased KR20180012833A (ko) 2015-05-29 2016-05-27 피지의 과잉 생산과 연관된 피부 상태를 치료하기 위한 폴리펩티드 및 항체

Country Status (7)

Country Link
US (1) US11117939B2 (https=)
EP (1) EP3307317B1 (https=)
JP (1) JP6853239B2 (https=)
KR (1) KR20180012833A (https=)
CN (1) CN107921125B (https=)
HK (1) HK1245664B (https=)
WO (1) WO2016191864A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102084163B1 (ko) * 2019-12-27 2020-05-15 주식회사 인투앱 프로피오니박테리움 아크네스 균으로부터 유래한 지방산 분해 효소에 특이적으로 결합하는 신규한 항체 및 이의 용도

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107325157B (zh) * 2017-08-07 2020-06-26 温州千瑞生物科技有限公司 调节皮脂分泌的肽以及包含其的化妆品
KR102268921B1 (ko) * 2019-12-10 2021-06-23 강원대학교산학협력단 p53을 활성화하는 펩타이드를 포함하는 조성물
WO2022051831A1 (pt) 2020-09-11 2022-03-17 Chemyunion Ltda. Composição, uso de composição, método cosmético e método para modular a produção de sebo
CN117003829A (zh) * 2023-07-24 2023-11-07 成都凯捷多肽科技有限公司 一种控油多肽化合物、制备方法及其应用
CN120923629A (zh) * 2024-05-08 2025-11-11 浙江大学医学院附属第一医院(浙江省第一医院) 一种阻断脂质合成的多肽在治疗肿瘤及脂质代谢异常疾病中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007289063A (ja) * 2006-04-25 2007-11-08 Shiseido Co Ltd しみ部位亢進遺伝子群を指標とした皮膚しみ形成予知方法、皮膚しみ形成抑制剤のスクリーニング方法
EP2120580B1 (en) * 2007-02-02 2017-12-27 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
WO2009121176A1 (en) 2008-03-31 2009-10-08 The University Of British Columbia Insulin-induced gene (insig) peptide compositions and methods for cytoprotection
CN102325789A (zh) * 2009-02-24 2012-01-18 希尔洛有限公司 用于治疗痤疮和其它病症的内脂素治疗药物
JP2011225455A (ja) * 2010-04-15 2011-11-10 Kao Corp Ｓｒｅｂｐ抑制剤
JP5353848B2 (ja) * 2010-09-24 2013-11-27 株式会社アドヴィックス 車両用ブレーキ装置
WO2013056148A2 (en) * 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
KR101910419B1 (ko) * 2012-02-10 2018-10-23 애경산업(주) 피지생성 억제용 화장료 조성물
JP5947061B2 (ja) * 2012-02-29 2016-07-06 花王株式会社 Ｓｒｅｂｐ１抑制剤
KR101528770B1 (ko) * 2013-06-13 2015-06-15 코스맥스 주식회사 사과 유래 폴리페놀을 함유하는 피지분비 완화 및 여드름 증상 개선용 화장료 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102084163B1 (ko) * 2019-12-27 2020-05-15 주식회사 인투앱 프로피오니박테리움 아크네스 균으로부터 유래한 지방산 분해 효소에 특이적으로 결합하는 신규한 항체 및 이의 용도

Also Published As

Publication number Publication date
CN107921125B (zh) 2021-06-08
JP6853239B2 (ja) 2021-03-31
US20180305419A1 (en) 2018-10-25
US11117939B2 (en) 2021-09-14
JP2018517767A (ja) 2018-07-05
EP3307317A4 (en) 2019-01-16
WO2016191864A1 (en) 2016-12-08
HK1245664B (en) 2020-06-26
EP3307317A1 (en) 2018-04-18
CN107921125A (zh) 2018-04-17
EP3307317B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
KR20180012833A (ko) 피지의 과잉 생산과 연관된 피부 상태를 치료하기 위한 폴리펩티드 및 항체
AU2002319050B2 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
HK1245664A1 (en) Polypeptides to treat skin conditions associated with overproduction of sebum
AU2002319049A1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP2922869B1 (en) Peptides that stimulate subcutaneous adipogenesis
EP1390403A2 (en) Peptides derived from neural thread proteins and their medical use
AU2002256587A1 (en) Peptides derived from neural thread proteins and their medical use
CN102666845B (zh) 磷酸酶和张力蛋白同系物(pten)抑制剂组合物,用途以及方法
KR20160136342A (ko) 모발 성장의 억제를 위한 오스테오폰틴 유도체를 포함하는 조성물
EP3717506A1 (en) Chimeric molecule for targeting c-myc in cells
JP2010239971A (ja) 細胞におけるペルオキシソームカタラーゼ機能の促進
KR20140089295A (ko) 피부 노화 개선용 조성물
KR20190139910A (ko) 브라시카세아에 단백질 추출물 및 그의 용도
EP2089419A2 (en) Inhibition of beta-amyloid aggregation
WO2014175333A1 (ja) 尋常性乾癬の治療および／または予防用皮膚外用剤
US11819537B2 (en) Preventive or therapeutic method for inflammatory skin disease
CA2526654A1 (en) Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease
US9334314B2 (en) Peptide compounds derived from melanotransferrin and uses thereof
JP2006515168A5 (https=)
CA3164094A1 (en) Treatment of skin conditions
KR102077984B1 (ko) 피부 주름 예방 및 개선용 조성물
HK1110083A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20260127

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2017 7037904

Appeal request date: 20241125

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024101002467

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2024101002467; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : APPEAL AGAINST DECISION TO DECLINE REFUSAL